These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 31320109)
21. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Nguyen GC; Bernstein CN; Bitton A; Chan AK; Griffiths AM; Leontiadis GI; Geerts W; Bressler B; Butzner JD; Carrier M; Chande N; Marshall JK; Williams C; Kearon C Gastroenterology; 2014 Mar; 146(3):835-848.e6. PubMed ID: 24462530 [TBL] [Abstract][Full Text] [Related]
22. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Sadowski DC; Bernstein CN; Bitton A; Croitoru K; Fedorak RN; Griffiths A; Can J Gastroenterol; 2009 Mar; 23(3):185-202. PubMed ID: 19319383 [TBL] [Abstract][Full Text] [Related]
23. Medical management of Crohn's disease. Cottone M; Renna S; Orlando A; Mocciaro F Expert Opin Pharmacother; 2011 Nov; 12(16):2505-25. PubMed ID: 21988215 [TBL] [Abstract][Full Text] [Related]
24. Methotrexate for induction of remission in refractory Crohn's disease. Alfadhli AA; McDonald JW; Feagan BG Cochrane Database Syst Rev; 2005 Jan; (1):CD003459. PubMed ID: 15674908 [TBL] [Abstract][Full Text] [Related]
25. The pharmacotherapeutic management of pediatric Crohn's disease. Zimmerman L; Bousvaros A Expert Opin Pharmacother; 2019 Dec; 20(17):2161-2168. PubMed ID: 31574236 [No Abstract] [Full Text] [Related]
26. Methotrexate for induction of remission in refractory Crohn's disease. Alfadhli AA; McDonald JW; Feagan BG Cochrane Database Syst Rev; 2003; (1):CD003459. PubMed ID: 12535475 [TBL] [Abstract][Full Text] [Related]
27. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Singh S; Allegretti JR; Siddique SM; Terdiman JP Gastroenterology; 2020 Apr; 158(5):1465-1496.e17. PubMed ID: 31945351 [TBL] [Abstract][Full Text] [Related]
28. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS; Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032 [TBL] [Abstract][Full Text] [Related]
29. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease. Ong C; Lim PT; Logarajah V; Liwanag MJ; Ang BX; Cher Y; Chiou FK; Kader A BMC Gastroenterol; 2018 Dec; 18(1):185. PubMed ID: 30541458 [TBL] [Abstract][Full Text] [Related]
30. Low dose naltrexone for induction of remission in Crohn's disease. Segal D; Macdonald JK; Chande N Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033 [TBL] [Abstract][Full Text] [Related]
31. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Hanauer S Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400 [TBL] [Abstract][Full Text] [Related]
32. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]. Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P; Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574 [TBL] [Abstract][Full Text] [Related]
33. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease. Grossi V; Lerer T; Griffiths A; LeLeiko N; Cabrera J; Otley A; Rick J; Mack D; Bousvaros A; Rosh J; Grossman A; Saeed S; Kay M; Boyle B; Oliva-Hemker M; Keljo D; Pfefferkorn M; Faubion W; Kappelman MD; Sudel B; Markowitz J; Hyams JS Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1748-56. PubMed ID: 25911120 [TBL] [Abstract][Full Text] [Related]
34. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. Levine A; Turner D; Pfeffer Gik T; Amil Dias J; Veres G; Shaoul R; Staiano A; Escher J; Kolho KL; Paerregaard A; Martin de Carpi J; Veereman Wauters G; Koletzko S; Shevah O; Finnby L; Sladek M Inflamm Bowel Dis; 2014 Feb; 20(2):278-85. PubMed ID: 24390062 [TBL] [Abstract][Full Text] [Related]
35. Enteral nutritional therapy for inducing remission of Crohn's disease. Zachos M; Tondeur M; Griffiths AM Cochrane Database Syst Rev; 2001; (3):CD000542. PubMed ID: 11686966 [TBL] [Abstract][Full Text] [Related]
36. Mild to moderate Crohn's disease: still room for step-up therapies? Bar-Meir S Dig Dis; 2009; 27(3):347-50. PubMed ID: 19786763 [TBL] [Abstract][Full Text] [Related]
37. American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Nguyen GC; Loftus EV; Hirano I; Falck-Ytter Y; Singh S; Sultan S; Gastroenterology; 2017 Jan; 152(1):271-275. PubMed ID: 27840074 [No Abstract] [Full Text] [Related]
38. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
39. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001 [TBL] [Abstract][Full Text] [Related]
40. Transcending conventional therapies: the role of biologic and other novel therapies. Sandborn WJ Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]